Anavex Life Sciences Corp.
2.4M
$261.33M
-16.37
$-0.54
No price alerts set. Add an alert to get notified!
-16.37
8.00
$-0.54
-48.89%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ABSI
Absci Corporation
|
$2.78 | -3.47% | -3.64 | $425.40M | 0.03 |
|
ARVN
Arvinas, Inc.
|
$10.10 | -7.08% | -8.11 | $648.67M | 0.02 |
|
ATXS
Astria Therapeutics, Inc.
|
$12.58 | 0.00 | -5.88 | $718.13M | 0.02 |
|
CTMX
CytomX Therapeutics, Inc.
|
$4.52 | 2.26% | -44.29 | $769.53M | 0.04 |
|
ERAS
Erasca, Inc.
|
$14.97 | -1.25% | -34.08 | $4.65B | 0.14 |
|
MBX
MBX Biosciences, Inc. Common Stock
|
$28.50 | 0.74% | -11.96 | $957.40M | 0.00 |
|
MGTX
MeiraGTx Holdings plc
|
$7.62 | 1.20% | -5.41 | $613.34M | -15.31 |
|
MLTX
MoonLake Immunotherapeutics
|
$17.32 | -2.42% | -4.91 | $1.24B | 0.25 |
|
RGNX
REGENXBIO Inc.
|
$7.76 | -6.05% | -2.07 | $400.52M | 2.54 |
|
VALN
Valneva SE
|
$6.17 | -2.37% | -4.16 | $530.89M | 1.95 |
* Peer stocks are selected based on market capitalization and sector
$13.99
$2.75
$0.00
0.00%
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
